×

Do you want to link to the external site and leave Amgen.ca?

You are now leaving Amgen Canada's website. Amgen Canada takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on the server or site.

×

Do you want to link to our other external sites and leave Amgen.ca?

You are now leaving Amgen Canada's website. Amgen Canada takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on the server or site.

  1. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). European Medicines Agency - Europa. [Online] May 24, 2012. [Cited: August 23, 2012.] http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2012/05/WC500127960.pdf.
  2. Schellekens, H. Biosimilar therapeutics – what do we need to consider? 2009, NDT Plus, 2, (Suppl 1), pp. i27-i36.
  3. Health Canada. Guidance For Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/seb-pbu_2010-eng.php.